Imunon (IMNN) Q3 2024 earnings summary

Executive summary

• Reported positive Phase II OVATION 2 results for IMNN-001 in advanced ovarian cancer, showing a median overall survival improvement of 11.1 months over standard care, with some patients approaching five years post-trial initiation.

• IMNN-001 demonstrated consistent benefits across multiple endpoints, including a 15.7-month median OS improvement in per-protocol patients and a hazard ratio of 0.41 for those treated with PARP inhibitors; progression-free survival improved by three months.

• IMNN-001 leverages TheraPlas technology for targeted IL-12 delivery, showing dose-dependent clinical improvement and minimal toxicity, with unanimous scientific advisory board support for a phase three trial.

• IMNN-101, a DNA-based COVID-19 booster, began Phase I trials in 2024, with topline safety and immunogenicity data expected by year-end.

• Internal GMP manufacturing in Alabama enables cost-effective production, and the product has received Fast Track and Orphan Drug designations in the U.S. and Europe.

Financial highlights

• Cash and cash equivalents stood at $10.3 million as of September 30, 2024, expected to fund operations into Q3 2025.

• Q3 2024 net loss was $4.9 million ($0.34/share), compared to $3.5 million ($0.37/share) in Q3 2023; nine-month 2024 net loss was $14.6 million ($1.39/share), unchanged from the prior year.

• R&D expenses increased to $3.3 million in Q3 2024 (up 65–66% year-over-year), mainly due to OVATION 2 and PlaCCine trial costs; G&A expenses decreased to $1.7 million.

• Raised $10 million in July/August 2024 through a registered direct offering and concurrent private placement of warrants.

• Net cash used in operating activities for the first nine months of 2024 was $14.4 million; net cash provided by financing activities was $9.1 million.

Outlook and guidance

• Phase three registration trial for IMNN-001 in advanced ovarian cancer is on track to begin in Q1 2025, pending FDA agreement, with a 500-patient pivotal study planned.

• Targeting a regulatory readout by end of 2029; trial design includes interim analyses for potential early submission.

• PlaCCine/IMNN-101 COVID-19 booster phase one data expected before year-end 2024, with active business development for partnerships.

• Preparing for an End-of-Phase 2 meeting with the FDA in November 2024.

• Management anticipates current cash resources are not sufficient to fund operations for the next twelve months and plans to seek additional capital.